Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VTGN

Vistagen Therapeutics Inc

Dec 11 • 04:00PM ET

2.51

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB NBIX ALNY BGNE ACAD CORT EDIT FATE AUPH MDGL

| Held by: VTI VXF PSIL IWC AVSC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.34	Insider Own	10.15%	Shs Outstand	27.06M	Perf Week	-4.20%
Market Cap	69.89M	Forward P/E	-	EPS next Y	-1.90	Insider Trans	0.00%	Shs Float	25.10M	Perf Month	-16.89%
Income	-39.57M	PEG	-	EPS next Q	-0.51	Inst Own	45.55%	Short Float	1.70%	Perf Quarter	-21.32%
Sales	0.88M	P/S	79.42	EPS this Y	-20.56%	Inst Trans	-15.75%	Short Ratio	2.09	Perf Half Y	-31.98%
Book/sh	3.44	P/B	0.73	EPS next Y	-3.41%	ROA	-54.69%	Short Interest	0.43M	Perf Year	-41.90%
Cash/sh	3.50	P/C	0.72	EPS next 5Y	-	ROE	-61.52%	52W Range	2.44 - 5.86	Perf YTD	-51.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	43.79%	ROI	-41.98%	52W High	-57.17%	Beta	0.79
Dividend TTM	-	Quick Ratio	13.29	Sales past 5Y	89.88%	Gross Margin	31.75%	52W Low	2.87%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	13.29	EPS Y/Y TTM	71.53%	Oper. Margin	-5207.38%	RSI (14)	35.75	Volatility	5.43% 5.80%
Employees	39	Debt/Eq	0.02	Sales Y/Y TTM	8.04%	Profit Margin	-4518.12%	Recom	1.00	Target Price	13.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	35.50%	Payout	-	Rel Volume	1.73	Prev Close	2.51
Sales Surprise	-18.56%	EPS Surprise	-7.47%	Sales Q/Q	-34.10%	Earnings	Nov 07 AMC	Avg Volume	203.36K	Price	2.51
SMA20	-5.34%	SMA50	-12.89%	SMA200	-31.76%	Trades		Volume	352,038	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Upgrade	Jefferies	Hold → Buy	$15
Aug-07-23	Upgrade	Maxim Group	Hold → Buy	$30
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	Jefferies	Buy → Hold
May-20-21	Initiated	Robert W. Baird	Outperform	$9
Feb-18-21	Initiated	Jefferies	Buy	$6
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy	$6
Feb-08-18	Reiterated	Chardan Capital Markets	Buy	$30 → $22
Mar-28-17	Initiated	Maxim Group	Buy	$4

Show Previous Ratings

Nov-14-24 08:30AM	Vistagen to Present at the Stifel 2024 Healthcare Conference (Business Wire)
Nov-08-24 02:31AM	Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with a ... (GuruFocus.com)
Nov-07-24 07:30PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update (Business Wire)
Nov-06-24 07:51AM	Vistagen Therapeutics Inc (VTGN) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
08:30AM	Loading…
Nov-05-24 08:30AM	Vistagen to Present at the 2024 Neuroscience Education Institute Congress (Business Wire)
Nov-01-24 08:30AM	Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 (Business Wire)
Oct-11-24 12:00PM	VistaGen Therapeutics (VTGN) Upgraded to Buy: Here's What You Should Know (Zacks)
Oct-09-24 06:20PM	Vistagen Therapeutics Inc (VTGN) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges (GuruFocus.com)
08:30AM	Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day (Business Wire)
Sep-24-24 04:52AM	Vistagen enrols first subject in Phase III trial of social anxiety disorder drug (Clinical Trials Arena)
Sep-23-24 08:30AM	Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder (Business Wire)
Sep-06-24 12:00PM	All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy (Zacks)
Aug-13-24 05:30PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:21PM	Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update (Business Wire)
08:30AM	Loading…
Aug-06-24 08:30AM	Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 (Business Wire)
Jul-26-24 06:20AM	3 Stocks Under $15 That Could Make You a Millionaire (InvestorPlace)
Jul-10-24 06:33AM	Vistagen secures new patents for PH80 migraine treatment (Pharmaceutical Technology)
Jul-09-24 08:30AM	Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine (Business Wire) +5.90%
Jun-27-24 08:30AM	Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year (Business Wire) +7.08%
Jun-12-24 08:52AM	VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q4 2024 (InvestorPlace)
08:02AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2024 Earnings Call Transcript (Insider Monkey)
Jun-11-24 04:20PM	Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update (Business Wire)
Jun-07-24 08:30AM	Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 (Business Wire)
May-29-24 08:30AM	Vistagen to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-24 08:30AM	Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference (Business Wire)
May-14-24 06:59AM	3 Must-Have Penny Stocks to Boost Your 2024 Portfolio (InvestorPlace)
May-13-24 10:00AM	Meme Stock Rebound: 3 Reddit Favorites Primed for a Resurgence (InvestorPlace)
May-07-24 08:30AM	Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference (Business Wire)
Apr-25-24 08:30AM	Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue (Business Wire)
07:13AM	Loading…
Apr-19-24 07:13AM	7 Stocks Under $15 Predicted to Boom in the Next 2 Years (InvestorPlace)
Apr-09-24 01:28PM	Millionaire Makers: 3 Stocks Under $10 Set to Skyrocket by 2027 (InvestorPlace)
08:30AM	Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference (Business Wire)
Apr-01-24 08:30AM	Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 (Business Wire)
Mar-31-24 10:00AM	Secret Superstars: 3 Unknown Stocks to Turn $5K into $100K by 2027 (InvestorPlace)
Mar-26-24 06:24AM	30 Countries with the Lowest Depression Rates (Insider Monkey)
Mar-11-24 08:30AM	Vistagen to Present at Stifel 2024 Virtual CNS Days (Business Wire)
Feb-28-24 08:30AM	Vistagen to Present at TD Cowen 44th Annual Health Care Conference (Business Wire)
Feb-21-24 09:55AM	Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect? (Zacks)
Feb-19-24 12:24PM	3 Revolutionary Biotech Stocks Poised for 10X Surge (InvestorPlace)
Feb-15-24 08:20AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2024 Earnings Call Transcript (Insider Monkey)
Feb-14-24 03:45PM	3 Hidden-Gem Biotech Stocks Ready to Ride a Massive Market Wave (InvestorPlace) +10.00%
Feb-13-24 04:59PM	Vistagen Therapeutics Inc (VTGN) Reports Fiscal 2024 Q3 Results: A Closer Look at Financials ... (GuruFocus.com)
04:20PM	Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update (Business Wire)
Feb-07-24 07:38AM	3 Penny Stocks to Buy for the Next Bull Run: February 2024 (InvestorPlace)
Feb-06-24 08:30AM	Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024 (Business Wire)
Jan-26-24 09:04AM	3 Penny Stocks to Turn $999 Into $1 Million: January 2024 (InvestorPlace)
Dec-29-23 08:40AM	How Vistagen (VTGN) Stock Stands Out in a Strong Industry (Zacks)
Dec-27-23 08:30AM	Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain (Business Wire)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -6.85%
Nov-11-23 01:03PM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2024 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:30PM	Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results (Business Wire) -6.17% -11.07%
Nov-08-23 08:30AM	Vistagen to Present at Stifel 2023 Healthcare Conference (Business Wire) -11.37%
Nov-07-23 08:30AM	Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences (Business Wire)
Nov-06-23 08:00AM	Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023 (Business Wire)
Oct-05-23 08:30AM	Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit (Business Wire) -9.18%
Oct-02-23 07:30AM	Vistagen Announces Pricing of $100 Million Underwritten Offering (Business Wire) -19.85%
Sep-21-23 04:43PM	The 7 Best Short-Squeeze Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-12-23 08:30AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder (Business Wire)
Sep-05-23 09:00AM	Vistagen and Fuji Enter Exclusive Negotiation Agreement for a Potential License to Develop and Commercialize Vistagens Investigational Menopausal Hot Flash Therapy, PH80 Nasal Spray, in Japan (Business Wire)
Aug-22-23 08:30AM	Vistagen Appoints Cindy Anderson as Chief Financial Officer (Business Wire) +7.68%
Aug-15-23 07:37AM	VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2024 Earnings Call Transcript (Insider Monkey) -9.77%
Aug-11-23 10:34AM	Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News (Zacks) -14.57%
Aug-10-23 04:21PM	Subsequent to the Release of Positive Phase 3 Trial Results, Vistagen Provides Corporate Update and Reports Fiscal 2024 First Quarter Financial Results (Business Wire) +6.82%
10:31AM	COMMODORE CAPITAL LP Acquires New Stake in Vistagen Therapeutics Inc (GuruFocus.com)
03:49AM	AffaMed Therapeutics Announces Partner Vistagen Reports Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (PR Newswire)
Aug-08-23 04:30PM	Vistagen To Report First Quarter Financial Results and Host Corporate Update Conference Call on August 10, 2023 (Business Wire) -43.14% -5.19%
Aug-07-23 05:46PM	Social anxiety nasal spray study results make Peninsula biotech's stock shoot up more than 600% (American City Business Journals) +676.79%
04:12PM	Biotech Firm Pops 677% on Social Anxiety Spray Trial Success (Bloomberg)
08:30AM	Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (Business Wire)
Jul-17-23 08:00AM	Vistagen Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Sprays Potential Antidepressant Activity via Peripheral Nasal Neurons without Entry into the Brain (Business Wire)
Jul-13-23 04:05PM	Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinsons Disease (Business Wire)
Jun-28-23 04:25PM	Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results (Business Wire)
Jun-27-23 04:30PM	Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023 (Business Wire)
Jun-23-23 08:30AM	Vistagen Regains Full Compliance with Nasdaq Listing Requirements (Business Wire)
Jun-21-23 08:30AM	Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder (Business Wire) -7.22%
Jun-16-23 12:36PM	Revolutionizing mental health treatment: Vistagen Therapeutics' nasal spray solution (News Direct)
08:30AM	Vistagen to Participate in the Maxim Group Healthcare Virtual Conference Hosted by M-Vest (Business Wire)
Jun-13-23 08:00AM	Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine (Business Wire) -10.91%
Jun-07-23 09:00AM	Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes (Business Wire) -9.21%
Jun-06-23 04:30PM	Vistagen to Present at Jefferies 2023 Global Healthcare Conference (Business Wire) -25.75%
09:25AM	Vistagen Announces Stockholder-Approved Reverse Stock Split (Business Wire)
Jun-01-23 08:30AM	Vistagen Presents Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting (Business Wire)
May-30-23 04:15PM	Vistagen to Present Fasedienol (PH94B) Safety and Exploratory Efficacy Data from Phase 3 Open-Label Social Anxiety Disorder Study at American Society for Clinical Psychopharmacology Annual Meeting (Business Wire) +6.12%
May-24-23 08:30AM	Vistagen Awarded Mental Health Americas Platinum Bell Seal for Workplace Mental Health (Business Wire)
Apr-19-23 08:30AM	Vistagen Presents New Fasedienol (PH94B) Research at 2023 Anxiety and Depression Association of America Conference (Business Wire)
Apr-06-23 08:30AM	Vistagen Receives New European Patent for AV-101 (Business Wire)
Mar-30-23 03:18PM	Social Anxiety Disorder Impacts Around 23.7M People In US, Vistagen Releases Details Around Nasal Spray Treatment Program For It (Benzinga)
08:30AM	FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder (Business Wire)
Mar-22-23 08:30AM	Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder (Business Wire) +16.37%
Mar-08-23 08:30AM	Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder (Business Wire)
Mar-02-23 08:30AM	Vistagen to Present at Cowen 43rd Annual Health Care Conference (Business Wire)
Mar-01-23 08:30AM	Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine (Business Wire)
Feb-08-23 12:49PM	VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial (Benzinga) -28.68%
Feb-07-23 06:15PM	VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:20PM	Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results (Business Wire)
Feb-06-23 09:09AM	Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023 (Business Wire) -16.83%
Feb-02-23 09:00AM	Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition (Business Wire) +8.91%
Jan-24-23 08:30AM	Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder (Business Wire)
Jan-19-23 08:30AM	Vistagen Poised To Begin Phase 1 Trial Of A Fast-Acting Antidepressant Nasal Spray In First Quarter Of 2023 (News Direct) -10.14%

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company, which engages in developing and commercializing medication and treatment for anxiety, depression, and other central nervous system disorders. Its product portfolio includes Fasedienol (PH94B) nasal spray for social anxiety disorder, Itruvone (PH10) nasal spray for depression disorders, AV-101 oral NMDR glycine site antagonist for depression and neurological disorders, PH15 acute treatment for improvement of cognition, PH80 acute management of vasomotor symptoms due to menopause, and PH284 acute management of Wasting syndrome (Cachexia). The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VTGN

Vistagen Therapeutics Inc

Upgrade your FINVIZ experience